Palivizumab

Motavizumab, however, was being designed to be more effective than Synagis, which is also known by its generic name palivizumab. ❋ Patricia Kowsmann (2010)

While the American Academy of Pediatrics recommends use of the injectible drug, known generically as palivizumab, for certain preemies, UnitedHealth was denying coverage for a subgroup of infants. ❋ Unknown (2008)

Motavizumab is ~tenfold more potent than its predecessor, palivizumab ❋ Jason S McLellan (2010)

Overall, RSV hospitalization occurred in 44 (8. 3\%) of the 528 infants in whom palivizumab prophylaxis had been requested but denied compared with 42 (2. 9\%) of 1,429 infants in whom the drug had not been requested, respectively, p less than 0.01. ❋ Unknown (2008)

In 2003, the AAP released guidelines that recommend the use of palivizumab in high-risk infants 32 to 35 weeks GA who are younger than six months of age at the start of RSV season, provided they have at least two of the following risk factors: attendance in day care, school-age siblings, exposure to environmental pollutants (excluding tobacco smoke), congenital airway anomalies, and severe neuromuscular disease. ❋ Unknown (2008)

In 528 / 1967 (27\%) infants, palivizumab prophylaxis was requested by the treating physician but was not authorized. ❋ Unknown (2008)

Synagis® (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease and is administered by intramuscular injection. ❋ Unknown (2008)

New data have emerged regarding three risk factors which may help pediatricians better identify which preterm infants are at high risk of severe respiratory syncytial virus (RSV) disease and may thus benefit from palivizumab ( ❋ Unknown (2008)